Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2007 May;2(3):169-76.
doi: 10.1097/COH.0b013e3280ef691e.

Neutralizing and other antiviral antibodies in HIV-1 infection and vaccination

David C Montefiori  1 , Lynn Morris, Guido Ferrari, John R Mascola
Affiliations

Neutralizing and other antiviral antibodies in HIV-1 infection and vaccination

David C Montefiori et al. Curr Opin HIV AIDS. 2007 May.

Abstract

Purpose of review: New findings continue to support the notion that broadly crossreactive neutralizing antibody induction is a worthwhile and achievable goal for HIV-1 vaccines. Immunogens are needed that can overcome the genetic variability and complex immune evasion tactics of the virus. Other antibodies might bridge innate and acquired immunity for possible beneficial vaccine effects. This review summarizes progress made over the past year that has enhanced our understanding of humoral immunity as it relates to HIV-1 vaccine development.

Recent findings: Although a clear path to designing an effective neutralizing antibody-based HIV-1 vaccine remains elusive, there is new information on how antibodies neutralize HIV-1, the epitopes involved, and clues to the possible nature of protective immunogens that keep this goal alive. Moreover, there is a greater understanding of HIV-1 diversity and its possible limits under immune pressure. Other antibodies might possess antiviral activity by mechanisms involving Fc receptor engagement or complement activation that would be of value for HIV-1 vaccines.

Summary: Recent developments strengthen the rationale for antibody-based HIV-1 vaccine immunogens and provide a stronger foundation for vaccine discovery.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Robbins JB, Schneerson R, Szu SC. Perspective: serum IgG antibody is sufficient to confer protection against infectious diseases by inactivating the inoculum. J Infect Dis. 1995;171:1387–1398. - PubMed
    1. Mascola JR. Defining the protective antibody response for HIV-1. Curr Mol Med. 2003;3:211–218. - PubMed
    1. Smith DM, Strain MC, Frost SDW, et al. Lack of neutralizing antibody response to HIV-1 predisposes to superinfection. Virology. 2006;355:1–5. This study reports the first anecdotal evidence that NAbs might protect against superinfection. - PubMed
    1. Dickover R, Garratty E, Yusim K, et al. Role of maternal autologous neutralizing antibody in selective perinatal transmission of human immunodeficiency virus type 1 escape variants. J Virol. 2006;80:6525–6533. This is the largest study of perinatally infected mother–infant pairs reported to date and includes a refined genetic analysis in addition to autologous NAb assays. The results strongly suggest that in-utero transmission of clade B HIV-1 involves neutralization-escape variants from the mother. They also imply that maternal autologous NAbs are associated with non-transmission. - PMC - PubMed
    1. Wu X, Parast AB, Richardson BA, et al. Neutralization escape variants of human immunodeficiency virus type 1 are transmitted from mother to infant. J Virol. 2006;80:835–844. This study shows that the perinatal transmission of non-clade B HIV-1 is associated with neutralization-escape variants in the transmitting mothers. This finding is in contrast with previous reports that sexual transmission in adults favors autologous neutralization-sensitive variants, suggesting that different antigenic variants are selected depending on the route of transmission. - PMC - PubMed